1600 Biotechnology and Organic Chemistry
Ex Parte Grawe et al SPIEGEL 103(a) BAYER SCHERING PHARMA AG MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Ex Parte Mahant et al ADAMS 103(a) FISH & ASSOCIATES, PC
Ex Parte Mahant et al ADAMS 103(a) FISH & ASSOCIATES, PC
1700 Chemical & Materials Engineering
Ex Parte Kim et al TIMM 102(b)/103(a) ROBERT E. BUSHNELL & LAW FIRM
Ex Parte Rodrigues et al KRATZ 102(b)/103(a) AKZO NOBEL INC.
Ex Parte Bakke HASTINGS 103(a) non-statutory obviousness-type double patenting CABOT CORPORATION
Ex Parte Francis et al DANG 101/103(a) U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
Ex Parte Murray et al BLANKENSHIP 103(a) HOWARD & HOWARD ATTORNEYS PLLC
3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
Ex Parte Amano et al MOHANTY 102(b)/112(1)/112(2) 37 C.F.R. § 41.50(b) KATTEN MUCHIN ZAVIS ROSENMAN
3700 Mechanical Engineering, Manufacturing, and Products & Design
Ex Parte Perini KERINS 103(a) McGLEW & TUTTLE, P.C.
See In re Keller, 642 F.2d 413 (CCPA 1981); In re Merck & Co., 800 F.2d 1091 (Fed. Cir. 1986) (nonobviousness can not be established by attacking references individually where rejections are based on combinations of references).
Keller, In re, 642 F.2d 413, 208 USPQ 871 (CCPA 1981) . . . . . . . . . . . . . . 707.07(f), 2145
Merck & Co., Inc., In re, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986) . . . . . . . .707.07(f), 716.02, 2143.02, 2144.08, 2144.09, 2145
AFFIRMED-IN-PART
1600 Biotechnology and Organic Chemistry
Ex Parte Jones et al PRATS 103(a) OSHA LIANG/MI
2100 Computer Architecture and Software
Ex Parte Saklecha et al THOMAS 102(e) STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
Ex Parte Iliff DANG 101/112(1)/102(b)/103(a) KNOBBE MARTENS OLSON & BEAR LLP
3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
Ex Parte Maughan et al CRAWFORD 112(2)/102(b)/103(a) Siemens Corporation
No comments :
Post a Comment